Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
    62.
    发明授权
    Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) 有权
    作为激素替代疗法(HRT)组合物组分的Mesoprogrestins(孕酮受体调节)

    公开(公告)号:US07629334B1

    公开(公告)日:2009-12-08

    申请号:US10433984

    申请日:2000-08-31

    IPC分类号: A61K31/56 C07J1/00 C07J6/00

    CPC分类号: A61K31/56

    摘要: The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred herein.

    摘要翻译: 使用中孕烯素作为药物组分用于制造用于激素替代疗法(HRT)的药物,以及作为与雌激素联合使用以用于制备用于HRT的药物的组合以及相应的HRT方法和方法 治疗激素缺乏和激素不规则症状。 中孕烯孕素被定义为在体内孕酮受体(PR)具有激动作用和拮抗活性的化合物。 他们将PR的功能稳定在激进和对抗的中间水平。 孕激素或抗孕激素不能达到相应的功能状态。 J867,J912,J956和J1042是本文优选的中孕酮。

    17alpha-fluorosteroids, pharmaceutical compositions containing 17alpha-fluorosteroids and a method of making them
    64.
    发明申请
    17alpha-fluorosteroids, pharmaceutical compositions containing 17alpha-fluorosteroids and a method of making them 失效
    17α-含氟类固醇,含有17α-荧光素的药物组合物及其制备方法

    公开(公告)号:US20050234027A1

    公开(公告)日:2005-10-20

    申请号:US11104736

    申请日:2005-04-13

    IPC分类号: A61K31/57 C07J3/00

    CPC分类号: C07J3/00

    摘要: New 17α-fluorosteroid compounds of formula (I) are disclosed: wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5α-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.

    摘要翻译: 公开了式(I)的新的17α-荧光素类化合物:其中R 1表示H或甲基; R 2和R 3各自表示H,Cl或甲基; 并且分别存在于类固醇环体系的C-6和C-7之间以及C-9和C-10之间的双键或单键。 这些化合物具有混合特征的活性谱,因此它们作为5α-还原酶的抑制剂和作为高效力的孕激素。 公开了含有它们的药物组合物。 它们适用于治疗由器官和组织中高水平雄激素引起的病症。 这些新化合物可以与其他荷尔蒙物质(如雌激素,睾酮和其他雄激素)一起使用,作为避孕药具和其他应用。

    11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
    65.
    发明授权
    11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring 失效
    11beta取代的19-nor-17-α-前 - 1,3,5(10) - 三烯-17β-酯与21,16α-内酯环

    公开(公告)号:US06956031B2

    公开(公告)日:2005-10-18

    申请号:US10397855

    申请日:2003-03-27

    CPC分类号: C07J17/00

    摘要: This invention relates to new 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring with a long-chain substituent in 11β-position of general formula II in which R11 is a long-chain alkyl radical that has a nitrogen atom that can be substituted in terminal position with a perfluoroalkyl group. The compounds act in a tissue-selective manner as pure antiestrogens and are suitable for the production of pharmaceutical agents because of these properties.

    摘要翻译: 本发明涉及具有21,16α-内酯环的新的19-nor-17α-前 - 1,3,5(10) - 三烯-17β-环,其通式II在11b位具有长链取代基 其中R 11是具有可以在末端被全氟烷基取代的氮原子的长链烷基。 化合物以组织选择性的方式作为纯抗雌激素起作用,并且由于这些性质而适用于制药。